China claims that four GlaxoSmithKline executives are involved in a massive bribery scheme to boost drug sales including travel costs, meeting expenses, and sexual favors going back over five years. Glaxo, for its part, is taking a tough stance, touting its zero-tolerance policy and sending key executives to personally handle the situation.
In this video, health-care analyst David Williamson discusses what this development means for Glaxo, how the company can turn this crisis into an opportunity, and what investors really need to be focused on in the pharma's pipeline.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.